This suppression of an aggressive neuroblastoma phenotype was concordant with that which we previously achieved via KDM1A knockdown in vitro and exceeded that of high-dose tranylcypromine treatment in vivo without the extreme adverse effects [10]. Here, KDM1A is linked to neuroblastoma.